Association of spermidine plasma levels with brain aging in a population-based study

Silke M. Wortha; Stefan Frenzel; Martin Bahls; Mohamad Habes; Katharina Wittfeld; Sandra Van der Auwera; Robin Bülow; Stephanie Zylla; Nele Friedrich; Matthias Nauck; Henry Völzke; Hans J. Grabe; Claudia Schwarz; Agnes Flöel

doi:10.1002/alz.12815

Association of spermidine plasma levels with brain aging in a population-based study

Silke M. Wortha, Stefan Frenzel, Martin Bahls, Mohamad Habes, Katharina Wittfeld, Sandra Van der Auwera, Robin Bülow, Stephanie Zylla, Nele Friedrich, Matthias Nauck, Henry Völzke, Hans J. Grabe, Claudia Schwarz, Agnes Flöel

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Introduction: Supplementation with spermidine may support healthy aging, but elevated spermidine tissue levels were shown to be an indicator of Alzheimer's disease (AD). Methods: Data from 659 participants (age range: 21–81 years) of the population-based Study of Health in Pomerania TREND were included. We investigated the association between spermidine plasma levels and markers of brain aging (hippocampal volume, AD score, global cortical thickness [CT], and white matter hyperintensities [WMH]). Results: Higher spermidine levels were significantly associated with lower hippocampal volume (ß = −0.076; 95% confidence interval [CI]: −0.13 to −0.02; q = 0.026), higher AD score (ß = 0.118; 95% CI: 0.05 to 0.19; q = 0.006), lower global CT (ß = −0.104; 95% CI: −0.17 to −0.04; q = 0.014), but not WMH volume. Sensitivity analysis revealed no substantial changes after excluding participants with cancer, depression, or hemolysis. Discussion: Elevated spermidine plasma levels are associated with advanced brain aging and might serve as potential early biomarker for AD and vascular brain pathology.

Original language	English (US)
Pages (from-to)	1832-1840
Number of pages	9
Journal	Alzheimer's and Dementia
Volume	19
Issue number	5
DOIs	https://doi.org/10.1002/alz.12815
State	Published - May 2023

Keywords

Alzheimer's disease
cortical thickness
epidemiology
hippocampal volume
spermidine
white matter hyperintensities

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Cellular and Molecular Neuroscience
Psychiatry and Mental health

Access to Document

10.1002/alz.12815

Cite this

@article{288debb3fef1481c87d8ce226e8abce9,

title = "Association of spermidine plasma levels with brain aging in a population-based study",

abstract = "Introduction: Supplementation with spermidine may support healthy aging, but elevated spermidine tissue levels were shown to be an indicator of Alzheimer's disease (AD). Methods: Data from 659 participants (age range: 21–81 years) of the population-based Study of Health in Pomerania TREND were included. We investigated the association between spermidine plasma levels and markers of brain aging (hippocampal volume, AD score, global cortical thickness [CT], and white matter hyperintensities [WMH]). Results: Higher spermidine levels were significantly associated with lower hippocampal volume ({\ss} = −0.076; 95% confidence interval [CI]: −0.13 to −0.02; q = 0.026), higher AD score ({\ss} = 0.118; 95% CI: 0.05 to 0.19; q = 0.006), lower global CT ({\ss} = −0.104; 95% CI: −0.17 to −0.04; q = 0.014), but not WMH volume. Sensitivity analysis revealed no substantial changes after excluding participants with cancer, depression, or hemolysis. Discussion: Elevated spermidine plasma levels are associated with advanced brain aging and might serve as potential early biomarker for AD and vascular brain pathology.",

keywords = "Alzheimer's disease, cortical thickness, epidemiology, hippocampal volume, spermidine, white matter hyperintensities",

author = "Wortha, {Silke M.} and Stefan Frenzel and Martin Bahls and Mohamad Habes and Katharina Wittfeld and {Van der Auwera}, Sandra and Robin B{\"u}low and Stephanie Zylla and Nele Friedrich and Matthias Nauck and Henry V{\"o}lzke and Grabe, {Hans J.} and Claudia Schwarz and Agnes Fl{\"o}el",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2023",

month = may,

doi = "10.1002/alz.12815",

language = "English (US)",

volume = "19",

pages = "1832--1840",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Association of spermidine plasma levels with brain aging in a population-based study

AU - Wortha, Silke M.

AU - Frenzel, Stefan

AU - Bahls, Martin

AU - Habes, Mohamad

AU - Wittfeld, Katharina

AU - Van der Auwera, Sandra

AU - Bülow, Robin

AU - Zylla, Stephanie

AU - Friedrich, Nele

AU - Nauck, Matthias

AU - Völzke, Henry

AU - Grabe, Hans J.

AU - Schwarz, Claudia

AU - Flöel, Agnes

PY - 2023/5

Y1 - 2023/5

N2 - Introduction: Supplementation with spermidine may support healthy aging, but elevated spermidine tissue levels were shown to be an indicator of Alzheimer's disease (AD). Methods: Data from 659 participants (age range: 21–81 years) of the population-based Study of Health in Pomerania TREND were included. We investigated the association between spermidine plasma levels and markers of brain aging (hippocampal volume, AD score, global cortical thickness [CT], and white matter hyperintensities [WMH]). Results: Higher spermidine levels were significantly associated with lower hippocampal volume (ß = −0.076; 95% confidence interval [CI]: −0.13 to −0.02; q = 0.026), higher AD score (ß = 0.118; 95% CI: 0.05 to 0.19; q = 0.006), lower global CT (ß = −0.104; 95% CI: −0.17 to −0.04; q = 0.014), but not WMH volume. Sensitivity analysis revealed no substantial changes after excluding participants with cancer, depression, or hemolysis. Discussion: Elevated spermidine plasma levels are associated with advanced brain aging and might serve as potential early biomarker for AD and vascular brain pathology.

AB - Introduction: Supplementation with spermidine may support healthy aging, but elevated spermidine tissue levels were shown to be an indicator of Alzheimer's disease (AD). Methods: Data from 659 participants (age range: 21–81 years) of the population-based Study of Health in Pomerania TREND were included. We investigated the association between spermidine plasma levels and markers of brain aging (hippocampal volume, AD score, global cortical thickness [CT], and white matter hyperintensities [WMH]). Results: Higher spermidine levels were significantly associated with lower hippocampal volume (ß = −0.076; 95% confidence interval [CI]: −0.13 to −0.02; q = 0.026), higher AD score (ß = 0.118; 95% CI: 0.05 to 0.19; q = 0.006), lower global CT (ß = −0.104; 95% CI: −0.17 to −0.04; q = 0.014), but not WMH volume. Sensitivity analysis revealed no substantial changes after excluding participants with cancer, depression, or hemolysis. Discussion: Elevated spermidine plasma levels are associated with advanced brain aging and might serve as potential early biomarker for AD and vascular brain pathology.

KW - Alzheimer's disease

KW - cortical thickness

KW - epidemiology

KW - hippocampal volume

KW - spermidine

KW - white matter hyperintensities

UR - http://www.scopus.com/inward/record.url?scp=85141351240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141351240&partnerID=8YFLogxK

U2 - 10.1002/alz.12815

DO - 10.1002/alz.12815

M3 - Article

C2 - 36321615

AN - SCOPUS:85141351240

SN - 1552-5260

VL - 19

SP - 1832

EP - 1840

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 5

ER -

Association of spermidine plasma levels with brain aging in a population-based study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this